• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution!

作者信息

Jones Philip M, Hobai Ion A, Murphy Patricia M

机构信息

Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA.

出版信息

Can J Anaesth. 2023 Aug;70(8):1281-1286. doi: 10.1007/s12630-023-02550-y. Epub 2023 Jul 19.

DOI:10.1007/s12630-023-02550-y
PMID:37466910
Abstract
摘要

相似文献

1
Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution!麻醉与胰高血糖素样肽-1受体激动剂：谨慎使用！
Can J Anaesth. 2023 Aug;70(8):1281-1286. doi: 10.1007/s12630-023-02550-y. Epub 2023 Jul 19.
2
Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!替尔泊肽与胰高血糖素样肽-1受体激动剂：安全始终是首要的！
Expert Opin Drug Saf. 2023 Jul-Dec;22(9):763-765. doi: 10.1080/14740338.2023.2247984. Epub 2023 Aug 18.
3
Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists.胰高血糖素样肽-1 受体激动剂治疗患者的严重急性肾衰竭。
Diabetes Res Clin Pract. 2014 Mar;103(3):e53-5. doi: 10.1016/j.diabres.2013.11.014. Epub 2013 Nov 20.
4
Glucagon-Like Peptide-1 Receptor Agonists-How Safe Are They?胰高血糖素样肽-1受体激动剂——它们有多安全？
JAMA Intern Med. 2022 May 1;182(5):520-521. doi: 10.1001/jamainternmed.2022.0335.
5
Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病合并非酒精性脂肪性肝病的 Meta 分析。
Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021.
6
Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.GLP-1 受体激动剂治疗患者的胆石症：随机对照试验的更新荟萃分析。
Diabetes Res Clin Pract. 2020 Mar;161:108087. doi: 10.1016/j.diabres.2020.108087. Epub 2020 Feb 19.
7
No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.GLP-1 受体激动剂治疗后无胰腺安全性担忧：心血管结局试验的汇总分析。
Diabetes Metab Res Rev. 2018 Nov;34(8):e3061. doi: 10.1002/dmrr.3061. Epub 2018 Sep 14.
8
Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.胰高血糖素样肽-1及其受体激动剂：它们在2型糖尿病管理中的作用。
Diabetes Metab Syndr. 2017 Jul-Sep;11(3):225-230. doi: 10.1016/j.dsx.2016.09.003. Epub 2016 Sep 15.
9
Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner.比较用于2型糖尿病的每周一次胰高血糖素样肽-1（GLP-1）受体激动剂，未发现明显的优胜者。
BMJ. 2015 Dec 9;351:h6702. doi: 10.1136/bmj.h6702.
10
Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration.使用胰高血糖素样肽-1受体激动剂相关的急性胆囊炎病例已上报美国食品药品监督管理局。
JAMA Intern Med. 2022 Oct 1;182(10):1104-1106. doi: 10.1001/jamainternmed.2022.3810.

引用本文的文献

1
2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists.2025年关于胰高血糖素样肽-1/葡萄糖依赖性促胰岛素多肽受体激动剂围手术期使用的澳大利亚糖尿病学会/澳大利亚和新西兰麻醉医师学会/胃肠病学会澳大利亚分会/澳大利亚肥胖症协会临床实践建议
Anaesth Intensive Care. 2025 Aug 14:310057X251355288. doi: 10.1177/0310057X251355288.
2
Role of Gastric Point-of-Care Ultrasound in Perioperative Management of Semaglutide.胃床旁超声在司美格鲁肽围手术期管理中的作用
Cureus. 2025 Jun 11;17(6):e85791. doi: 10.7759/cureus.85791. eCollection 2025 Jun.
3
The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care.

本文引用的文献

1
AI search of Neanderthal proteins resurrects 'extinct' antibiotics.对尼安德特人蛋白质的人工智能搜索复活了“已灭绝”的抗生素。
Nature. 2023 Jul 28. doi: 10.1038/d41586-023-02403-0.
2
Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide.在近期开始使用司美格鲁肽的非肥胖志愿者中，使用司美格鲁肽对胃超声中残胃固体存在的影响：一项前瞻性观察研究。
Can J Anaesth. 2023 Aug;70(8):1300-1306. doi: 10.1007/s12630-023-02549-5. Epub 2023 Jul 19.
3
Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report.
胰高血糖素样肽-1激动剂对肌肉骨骼健康和骨科护理的影响。
Curr Rev Musculoskelet Med. 2025 May 15. doi: 10.1007/s12178-025-09978-3.
4
Postoperative Aspiration Pneumonia Among Adults Using GLP-1 Receptor Agonists.使用GLP-1受体激动剂的成人术后吸入性肺炎
JAMA Netw Open. 2025 Mar 3;8(3):e250081. doi: 10.1001/jamanetworkopen.2025.0081.
5
Impact of Preoperative Glucagon-Like Peptide-1 Receptor Agonist on Outcomes Following Major Surgery.术前胰高血糖素样肽-1受体激动剂对大手术后结局的影响。
World J Surg. 2025 Mar;49(3):698-707. doi: 10.1002/wjs.12484. Epub 2025 Jan 9.
6
Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS).围手术期胰高血糖素样肽-1受体激动剂（GLP-1RA）与胃床旁超声检查（POCUS）。
POCUS J. 2024 Nov 15;9(2):39-41. doi: 10.24908/pocus.v9i2.17700. eCollection 2024.
7
A Scoping Review of GLP-1 Receptor Agonists: Are They Associated with Increased Gastric Contents, Regurgitation, and Aspiration Events?胰高血糖素样肽-1受体激动剂的范围综述：它们是否与胃内容物增加、反流和误吸事件有关？
J Clin Med. 2024 Oct 23;13(21):6336. doi: 10.3390/jcm13216336.
8
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.用于治疗肥胖症的胰高血糖素样肽-1受体激动剂：减肥效果、耐受性、副作用及风险
Obes Pillars. 2024 Aug 31;12:100127. doi: 10.1016/j.obpill.2024.100127. eCollection 2024 Dec.
9
Perioperative Management of Patients with Diabetes and Cancer: Challenges and Opportunities.糖尿病合并癌症患者的围手术期管理：挑战与机遇
Cancers (Basel). 2024 Aug 11;16(16):2821. doi: 10.3390/cancers16162821.
10
Comparison of societal guidance on perioperative management of glucagon-like peptide-1 receptor agonists: implications for clinical practice and future investigations.比较胰高血糖素样肽-1 受体激动剂围手术期管理的社会指导：对临床实践和未来研究的影响。
Can J Anaesth. 2024 Sep;71(9):1302-1315. doi: 10.1007/s12630-024-02810-5. Epub 2024 Aug 26.
禁食患者在接受司美格鲁肽减肥治疗时出现麻醉反流：病例报告。
Can J Anaesth. 2023 Aug;70(8):1397-1400. doi: 10.1007/s12630-023-02521-3. Epub 2023 Jun 6.
4
Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.司美格鲁肽、胃排空延迟和术中误吸：病例报告。
Can J Anaesth. 2023 Aug;70(8):1394-1396. doi: 10.1007/s12630-023-02440-3. Epub 2023 Mar 28.
5
Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.胃食管十二指肠镜检查中胰高血糖素样肽-1 受体激动剂治疗与胃残留物的关系。
J Diabetes Investig. 2023 Jun;14(6):767-773. doi: 10.1111/jdi.14005. Epub 2023 Mar 15.
6
Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy.围手术期使用司美格鲁肽与残余胃内容物的关系：对接受择期上消化道内镜检查患者的回顾性分析
J Clin Anesth. 2023 Aug;87:111091. doi: 10.1016/j.jclinane.2023.111091. Epub 2023 Mar 2.
7
Impact of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) on Food Content During Esophagogastroduodenoscopy (EGD).胰高血糖素样肽-1 受体激动剂（GLP-1RA）对食管胃十二指肠镜检查（EGD）期间食物含量的影响。
Ann Pharmacother. 2022 Aug;56(8):922-926. doi: 10.1177/10600280211055804. Epub 2021 Nov 2.
8
Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.司美格鲁肽皮下制剂和口服制剂的疗效。
Front Endocrinol (Lausanne). 2021 Jun 25;12:645617. doi: 10.3389/fendo.2021.645617. eCollection 2021.
9
Realizing Shared Decision-making in Practice.在实践中实现共同决策
JAMA. 2019 Sep 3;322(9):811-812. doi: 10.1001/jama.2019.9797.
10
Pre-operative gastric ultrasound - should we look inside Schrödinger's gut?术前胃部超声检查——我们应该窥视薛定谔的肠道内部吗？
Anaesthesia. 2019 Jan;74(1):109-112. doi: 10.1111/anae.14516.